Nkarta, Inc. (NASDAQ:NKTX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 63.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 56,919 shares of the company’s stock after selling 99,858 shares during the period. Jane Street Group LLC’s holdings in Nkarta were worth $257,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of NKTX. Bank of New York Mellon Corp grew its stake in shares of Nkarta by 80.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 172,162 shares of the company’s stock worth $1,017,000 after purchasing an additional 76,612 shares during the period. Rhumbline Advisers lifted its position in shares of Nkarta by 65.1% during the 2nd quarter. Rhumbline Advisers now owns 84,011 shares of the company’s stock valued at $496,000 after buying an additional 33,117 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Nkarta by 11,164.3% during the 2nd quarter. Acadian Asset Management LLC now owns 303,461 shares of the company’s stock valued at $1,792,000 after buying an additional 300,767 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Nkarta by 49.9% during the 2nd quarter. American Century Companies Inc. now owns 72,205 shares of the company’s stock valued at $427,000 after buying an additional 24,033 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in shares of Nkarta during the 2nd quarter valued at approximately $26,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Trading Down 1.7 %

Shares of NASDAQ:NKTX opened at $2.35 on Friday. The business has a 50-day moving average price of $2.61 and a 200 day moving average price of $4.30. The company has a market capitalization of $165.84 million, a price-to-earnings ratio of -1.25 and a beta of 0.85. Nkarta, Inc. has a 12-month low of $2.08 and a 12-month high of $16.24.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NKTX. HC Wainwright decreased their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Rodman & Renshaw started coverage on Nkarta in a report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective on the stock. Mizuho reduced their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Finally, Needham & Company LLC reduced their price target on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $15.00.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.